Selected Scientific Publications
(not including clinical studies)
Molecular Pathways and Mechanisms of HER2 in Cancer Therapy. Raghav KPS & Moasser MM. Clin Cancer Res 2023; 29: 2351-2361. PMID: 36574481. PMCID: PMC10293474
Moasser MM. Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions. Cancer Res 2022. 82: 2811-2820. PMID 35731927
Wu CH, Wang L, Yang CY, Wen KW, Hinds BR, Gill R, McCormick F, Moasser M, Pincus L, Ai WZ. Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models. Blood Adv 2022. 6: 2290-2302. PMID 34872108. PMCID PMC9006301
Ruiz-Saenz A, Atreya CE, Wang C, Pan B, Dreyer CA, Brunen D, Prahallad A, Munoz DP, Ramms DJ, BurghiV, Spassov DS, Fewings E, Hwang YC, Cowdrey C, Moelders C, Schwarzer C, Wolf DM, Hann B, VandenBerg SR, Shokat K, Moasser MM, Bernards R, Gutkind JS, VantVeer L, Coppe JP. A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAFV600E colorectal tumors. Nat Cancer 2023; 4: 240-256. PMID 36759733. PMCID PMC9970872.
Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM. Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Cell Reports 2022, 38: 110285. PMID 35108526
Campbell MR, Ruiz-Saenz A, Peterson E, Agnew C, Ayaz P, Garfinkle S, Littlefield P, Steri V, Oeffinger J, Sampang M, Shan Y, Shaw DE, Jura N, Moasser MM. Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. Cell Reports 2022, 38: 110291. PMID 35108525
Pollan SG, Teng P, Jan YJ, Livingstone J, Huang C, Kim M, Mariscal J, Rodriguez M, Chen JF, You S, DiViaio D, Boutros PC, Chan KS, Rasorenova O, Cress A, Spassov D, Moasser M, Posados EM, Freedlan SJ, Freeman MR, Zheng JJ, Knudsen BS. Loss of CDCP1 triggers FAK activation in detached prostate cancer cells. Am J Clin Exp Urol 2021; 9:350-366. PMID: 34541033 PMCID: PMC8446766
Majumder A, Sandhu M, Banerji D, Steri V, Olshen A, Moasser MM. The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers. Sci Rep. 2021; 11: 9091. PMID 33907275. PMCID PMC807937
Ruiz-Saenz A, Zahedi F, Peterson E, Yoo A, Dreyer CA, Spassov DS, Oses-Prieto J, Burlingame A, Moasser MM. An analysis of the phosphorylation states of Src in cancer cells suggesting deregulation mediated through the unique domain. Mol Cancer Res 2021. 19: 957-967. PMID 33727342 PMCID PMC8178206
Abdel Aziz MH, Fan Y, Liu L, Moasser MM, Fu H, Jura N, Arkin MR. Expression and purification of active human kinases using Pichia pastoris as a general-purpose host. Protein Expr Purif 2021. 179: 105780. PMID 33115654
Wu C, Yang C, Wang L, Gao H, Rakhshandehroo T, Afghani S, Pincus L, Balassanian R, Rubenstein J, Gill R, Bandyopadhyay S, McCormick F, Moasser M, Ai WZ. Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC. J Invest Dermatol 2020. 141:364-73. PMID 32603749.
Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN. Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nat Commun 2020; 11: 3584. PMID 32681091. PMCID PMC7367885.
Kumar R, George B, Campbell MR, Verma N, Paul AM, Melo-Alvim C, Ribiero L, Pillai MR, da Costa LM, Moasser MM. HER family in cancer progression: From discovery to 2020 and beyond. Adv Cancer Res 2020. 147: 109-160. PMID 32593399.
Coppé JP, Mori M, Pan B, Yau C, Wolf DM, Ruiz-Saenz A, Brunen D, Prahallad A, Cornelissen-Steijger P, Kemper K, Posch C, Wang C, Dreyer CA, Krijgsman O, Lee PRE, Chen Z, Peeper DS, Moasser MM, Bernards R, van 't Veer LJ. Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. Nat Cell Biol 2019; 21: 778-790. PMID 31160710
Spassov DS, Ruiz-Saenz A, Piple A, Moasser MM. A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src. Cell Rep 2018; 25: 449-463. PMID 30304684
Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia NP, Moasser MM. HER2 amplification in tumors activates PI3K/Akt signaling independent of HER3. Cancer Research 2018;78:3645-365. PMID 29760043
Ruiz Saenz A & Moasser MM. Targeting HER2 by combination therapies. J Clin Oncol 2018. 36: 808-811. PMID 29381433
Pollan SG, Huang F, Sperger JM, Lang JM, Morrissey C, Cress AE, Chu CY, Bhowmick NA, You S, Freeman MR, Spassov DS, Moasser MM, Carter WG, Satapathy SR, Shah K, Knudsen BS. Regulation of inside-out β1-integrin activation by CDCP1. Oncogene 2018 37:2817-2836. PMID 29511352
Enyindah-Asonye G, Li Y, Ruth JH, Spassov DS, Hebron KE, Zijlstra A, Moasser MM, Wang B, Singer NG, Cui H, Ohara RA, Rasmussen SM, Fox DA, Lin F. CD318 is a ligand for CD6. Proc Natl Acad Sci U S A. 2017;114: E6912-E6921. PMID 28760953
Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DA, Ahuja D, Moasser MM, Park CC. Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin. Breast Cancer Res Treat. 2016; 155:431-40. PMID 26860947. PMCID: PMC4767608.
Chang YH, Korkola J, Amin DN, Moasser MM, Carmena JM, Gray JW, Tomlin CJ. Disentangling multidimensional spatio-temporal data into their common and aberrant responses. PLoS One. 2015; 10:e0121607. PMID: 25901353. PMCID: PMC4406848.
Moasser MM, Krop IE. The Evolving Landscape of HER2 Targeting in Breast Cancer. JAMA Oncol. 2015 1:1154-61. PMID: 26204261.
Amin DN, Ruiz-Saenz A, Gulizia N, Moasser MM. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib. Oncotarget. 2015; 6: 41123-33. PMID 26516700. PMCID: PMC4747394.
Amin DN, Ahuja D, Yaswen P, Moasser MM. A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers. Mol Cancer Ther. 2015; 14: 1-13. PMID 26438156. PMCID: PMC4674361.
Campbell MR and Moasser MM. HER targeting in HER2-negative Breast Cancers: Looking for the HER3 positive. Clin Cancer Res 2015; 21:2886-8. PMID 25609069. PMCID: PMC4490014.
Ruiz-Saenz A, Sandhu M, Carrasco Y, Maglathlin RL, Taunton J, Moasser MM. Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum. Oncogene 2015; 34:5288-94. PMID 25619841. PMCID: PMC4515412.
Moasser MM. Two Dimensions in Targeting HER2. J Clin Oncol 2014; 32: 2074-7. PMID: 2486026. PMCID: PMC4517047.
Littlefield P, Moasser MM, Jura N. An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase. Chem Biol. 2014; 21:453-8. PMID: 24656791. PMCID: PMC4018233.
Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM. Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells. Cancer Res. 2013;73:1168-79. PMID: 23243018. PMCID: PMC3563920.
Amin DN, Sergina N, Lim L, Goga A, Moasser MM. HER3 signaling is regulated through a multitude of redundant mechanisms in HER2-driven tumor cells. Biochemical J 2012; 447:417-25. PMID:22853430.
Spassov DS, Wong CH, Harris G,McDonough S, Phojanakong P, Wang D, Hann B, Bazarov AV, Yaswen P, Khanafshar E, Moasser MM. A tumor suppressing function in the epithelial adhesion protein Trask. Oncogene 2012; 31:419-31. PMID: 21706059. PMCID: PMC3184310
Spassov DS, Wong CH, Moasser MM. Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state. Cell Cycle 2011; 10: 1225-32. PMID: 21490433.
Spassov DS, Wong CH, Ahuja D, Moasser MM. The structural features of Trask that mediate its anti-adhesive function. PLoS One 2011; 6: e19154. PMID: 21559459. PMCID: PMC3084758.
Spassov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, Moasser MM. Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol. 2011; 31:766-82. PMID: 21189288; PMCID: PMC3028653.
Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 2010; 21: 944-50. PMID: 20816829; PMCID: PMC2991618.
Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 2010; 16:1373-83. PMID: 20179223; PMCID: PMC2831167.
Amin DA, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Science TM 2010; 2(16): p16ra7. PMID: 20371474; PMCID: PMC3033659.
Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen L, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound paclitaxel for advanced solid tumor malignanices. Clin Cancer Res 2009; 15: 5569-75. PMID: 19706807; PMCID: PMC3029022.
Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM. The Transmembrane src Substrate Trask Is an Epithelial Protein that Signals during Anchorage Deprivation. Am J Pathol 2009 174: 1756-1765. PMID: 19349359; PMCID: PMC2671264.
Arkin M & Moasser MM. HER2 directed small molecule antagonists. Curr Opin Investigat Drugs 2008; 9: 1264-76. PMID: 19037833; PMCID: PMC3031872.
Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM The src phosphorylation of its epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res 2009; 15: 2311-2322. PMID: 19318475; PMCID: PMC3023342.
Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM. MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging. 2009; 29:1071-9. PMID: 19388114.
Torbett NE, Luna A, Knight ZA, Houk A, Moasser MM, Weiss W, Shokat KA and David Stokoe. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isotype-selective inhibition. Biochemical J 2008; 415: 97-110. PMID: 18498248; PMCID: PMC3079392.
Chien AJ & Moasser MM. Cellular Mechanisms of Resistance to Anthracyclines and Taxanes in Cancer: Intrinsic and Acquired. Semin Oncol 35(Suppl 2); S1-S14 (2008). PMID: 18410794.
Wieduwilt WJ & Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell & Mol Life Sci 2008; 65: 1566-84. PMID: 18259690; PMCID: PMC3060045.
Sergina NV & Moasser MM. The HER family: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 13; p527-534 (2007). PMID: 17981505; PMCID: PMC3035105.
Hsieh AC & Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 97; p453-457 (2007). PMID: 17667926; PMCID: PMC2360352.
Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26; p6577-6592 (2007). PMID: 17486079; PMCID: PMC3071580.
Moasser MM. The oncogene HER2; Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26; p6469-6487 (2007). PMID: 17471238; PMCID: PMC3021475.
Moasser MM, Wilmes LJ, Wong CH, Li K, Wang D, Hom YK, Hann B, Hylton NM. Improved tumor vascular function following high dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Mag Res Imag 2007 26:1618-25. PMID: 17968965; PMCID: PMC3024590.
Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3. Nature 445; p437-441 (2007). PMID: 17206155; PMCID: PMC3025857.
Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. Adhesion Signaling by a novel mitotic substrate of src kinases. Oncogene 24; p5333-5343 (2005).
Mizenina OA & Moasser MM. S-phase Inhibition of Cell Cycle Progression by a Novel Class of Pyridopyrimidine Tyrosine Kinase Inhibitors. Cell Cycle 3; p796-803 (2004).
She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib (ZD1839, Iressa) in PTEN null HER overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive PI3K/Akt pathway signaling. Clinical Cancer Research 2003; 9: 4340-4346.
Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. A novel pyridopyrimidine inhibitor of Abl kinase is a picomolar inhibitor of Bcr-abl driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clinical Cancer Research 2003; 9: 1267-1273.
Moasser MM & Rosen N. Molecular markers in the farnesyltransferase inhibitor (FTI) therapy of breast cancers. Breast Cancer Research & Treatment 2002; 73:135-144.
Munster PN. Srethapakdi M. Moasser MM. Rosen N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells Cancer Research 2001; 61:2945-52.
Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 (‘Iressa’) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumors. Cancer Research 2001; 61: 7184-7188.
Sepp-Lorenzino L, Tjaden G, Moasser MM, Timaul N, Ma Z, Kohl NE, Gibbs JB, Oliff A, Rosen N, Scher HI. Farnesyl:protein transferase inhibitors as potential agents for the management of prostate cancer. Prostate Cancer and Prostatic Diseases 2001; 4: 33-43.
Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, and Rosen N. Inhibition of src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Research 1999; 54: 6145-6152.
Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Baalog A, Su D, Danishefsky SJ, and Rosen N. Farnesyl Transferase Inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl. Acad. Sci. USA 1999; 95: 1369-1374.